SCHEMBL6515376

SCHEMBL6515376

Cc1c2c(=O)n(CCCN3C(=O)c4ccccc4C3=O)c3ccc(Cl)cc3c2nn1C1CCCCO1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
CHEK1 O14757 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
TP53 P04637 1/20 0.35
CNR2 P34972 3/20 0.35
CNR1 P21554 1/20 0.33
DGAT2 Q96PD7 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP3A4 P08684 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DRD1 P21728 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6514840 0.87 KMT2A (0.36) MAPTKMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL6508624 0.85 KMT2A (0.35) MAPTKMT2AMEN1RXFP1SMN1; SMN2
SCHEMBL6511094 0.83 CHEK1 (0.41) MAPTKMT2ACHEK1SMN1; SMN2LMNA
SCHEMBL6522000 0.82 CHEK1 (0.41) MAPTKMT2ACHEK1LMNATDP1
SCHEMBL6516690 0.82 CHEK1 (0.42) MAPTKMT2ACHEK1LMNATDP1
SCHEMBL6514165 0.81 CHEK1 (0.39) MAPTKMT2ACHEK1SMN1; SMN2LMNA
SCHEMBL6511866 0.81 CHEK1 (0.38) MAPTKMT2ACHEK1SMN1; SMN2LMNA
SCHEMBL6511027 0.79 ATR (0.42) CHEK1CNR2
SCHEMBL6515427 0.78 ALDH1A1 (0.41) MAPTKMT2AMEN1CHEK1SMN1; SMN2
SCHEMBL6507186 0.78 HTR2C (0.41) CHEK1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 MAPT 3744/4885KMT2A 1919/4885MEN1 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.